Form 4: Coherus Oncology Director Granted 112,000 Stock Options
Insider Transaction Report
Coherus Oncology, Inc. Director Michael Lee Ryan was granted 112,000 stock options with an exercise price of $0.7904, vesting one year from June 11, 2025.
Summary
- Michael Lee Ryan, a Director of Coherus Oncology, Inc. (CHRS), was the reporting person for this transaction.
- On June 12, 2025, Mr. Ryan acquired 112,000 stock options.
- The stock options have an exercise price of $0.7904 per share.
- The options are scheduled to vest 100% on June 11, 2026, contingent upon Mr. Ryan's continued service relationship with the Issuer.
- The expiration date for these stock options is June 12, 2035.
- Following this reported transaction, Michael Lee Ryan directly beneficially owns 112,000 derivative securities.
Sentiment
Score: 6
Explanation: The grant of stock options to a director is a routine compensation event that aligns the director's interests with shareholder value, indicating a positive incentive structure.
Positives
- The grant of 112,000 stock options to Director Michael Lee Ryan aligns his long-term financial interests with those of the company's shareholders.
- The options have a long expiration date of June 12, 2035, providing a sustained incentive for the director to contribute to long-term value creation.
Negatives
- NA
Risks
- NA
Future Outlook
The stock options are set to vest 100% on June 11, 2026, contingent on the director's continued service, indicating an expectation of continued tenure and alignment with the company's long-term performance.
Management Comments
- NA
Industry Context
This Form 4 filing is a standard disclosure of an insider equity transaction, common across all publicly traded companies, reflecting compensation or incentive grants to directors or executives. It indicates routine corporate governance practices related to executive and director compensation.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Executive Compensation | Grant of 112,000 stock options to Director Michael Lee Ryan as part of the company's equity incentive plan. | 06/12/2025 | Aligns director's long-term interests with shareholder value through performance-based incentives and retention. |
Legal Proceedings
- NA
Related Party Transactions
- Grant of 112,000 stock options to Michael Lee Ryan, a Director of Coherus Oncology, Inc., with an exercise price of $0.7904 per share, representing a transaction between the company and a related party.
Stakeholder Impact
- Shareholders: The grant of stock options to a director aims to align management's interests with shareholder value creation, potentially leading to improved long-term performance.
Next Steps
- Continued service of Michael Lee Ryan with Coherus Oncology, Inc. until at least June 11, 2026, for the options to fully vest.
- Potential exercise of stock options by Michael Lee Ryan between June 11, 2026, and June 12, 2035.
Key Dates
| Date | Description |
|---|---|
| 06/11/2025 | Base date for the one-year vesting period of the stock options. |
| 06/12/2025 | Date of the stock option grant transaction. |
| 06/13/2025 | Date the Form 4 filing was signed. |
| 06/11/2026 | Vesting date for 100% of the 112,000 stock options, subject to continued service. |
| 06/12/2035 | Expiration date of the stock options. |
Keywords
Coherus Oncology, CHRS, Stock Option, Director, SEC Form 4, Insider Transaction, Equity Grant, Michael Lee Ryan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.